CLARITY PHARMACEUTICALS LTD

0.38%

$2.63

Market Cap $845.1M

Healthcare Biotechnology

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Latest Threads

Tag

Subject

CU6

Ann: SECuRE trial update

2 3

03:14

137

43K

03:14

Last post ttppxx

137

43K

CU6

CU6 - ASX Charts

29 30 31

16/03/25

1.8K

715K

16/03/25

Last post

slick

1.8K

715K

CU6

CU6 - Media and Industry News

13 14 15

10/03/25

856

387K

10/03/25

Last post ttppxx

856

387K

CU6

Broker Consensus

09/03/25

2.3K

09/03/25

Last post

Davisite

2.3K

CU6

Ann: Cleansing Notice

05/03/25

320

05/03/25

Last post

ASX News

320

CU6

Ann: Application for quotation of securities - CU6

05/03/25

276

05/03/25

Last post

ASX News

276

CU6

Ann: Half Yearly Report and Accounts

05/03/25

13K

05/03/25

Last post ma420

13K

CU6

Ann: Clarity signs Cu-64 Supply Agreement with UQ

05/03/25

533

05/03/25

Last post

ASX News

533

See All Discussions

Timeline

Cleansing Notice
05 Mar 13:57	Share

Application for quotation of securities - CU6
05 Mar 13:51	Share

Clarity signs Cu-64 Supply Agreement with UQ
05 Mar 09:57	Share

SECuRE trial update
05 Mar 09:55	Share

Half Yearly Report and Accounts
28 Feb 15:52	Share

Appendix 4D
28 Feb 15:52	Share

Clarity receives US FDA FTD for the treatment of mCRPC
19 Feb 09:31	Share

Response to ASX Cleansing Notice Timing Letter
18 Feb 11:04	Share

Cleansing Notice
11 Feb 14:00	Share

Application for quotation of securities - CU6
11 Feb 13:53	Share

Clarity expands pipeline with Cu-64/67 SAR-trastuzumab
11 Feb 09:40	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jan 11:57	Share

Cleansing Notice
29 Jan 18:54	Share

Application for quotation of securities - CU6
29 Jan 18:48	Share

Clarity to present COBRA and CLARIFY abstracts
28 Jan 09:37	Share

Clarity receives U.S. FDA Fast Track Designation
24 Jan 09:40	Share

Cleansing Notice
22 Jan 15:46	Share

Application for quotation of securities - CU6
22 Jan 15:41	Share

Notification of cessation of securities - CU6
08 Jan 18:05	Share

Cleansing Notice
18 Dec 16:01	Share

Application for quotation of securities - CU6
18 Dec 15:53	Share

Novel FAP-targeted radiopharmaceutical
18 Dec 09:57	Share

S&P DJI Announces December 2024 Quarterly Rebalance
06 Dec 17:08	Share

Cleansing Notice
06 Dec 08:57	Share

Application for quotation of securities - CU6
06 Dec 08:56	Share

Last patient assessment completed for SARTATE trial
28 Nov 09:57	Share

First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA
26 Nov 09:56	Share

Change of Director's Interests - All Directors
26 Nov 09:31	Share

Notification regarding unquoted securities - CU6
25 Nov 14:34	Share

Results of Meeting
20 Nov 13:27	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.63		Change 0.010(0.38%)		Mkt cap ! $845.1M

Open	High	Low	Value	Volume
$2.62	$2.68	$2.57	$5.392M	2.052M

Buyers (Bids)

No.	Vol.	Price($)
1	6906	$2.62

Sellers (Offers)

Price($)	Vol.	No.
$2.64	750	1

View Market Depth

No.	Vol.	Price($)
2	7734	2.600
1	20000	2.580
3	1505	2.570
2	9000	2.560
9	51893	2.550

Price($)	Vol.	No.
2.650	10669	2
2.670	14981	1
2.680	9328	1
2.690	9293	1
2.700	1518	1

Last trade - 16.10pm 14/03/2025 (20 minute delay)

CU6 (ASX) Chart

CLARITY PHARMACEUTICALS LTD

Latest Threads

Timeline

Featured News

Latest Videos

Clarity Pharmaceuticals' (ASX:CU6) theranostic prostate cancer trial progresses to highest dose level

10 Aug 2023 12:13 (AEST)

Latest Articles

Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancer

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity Pharmaceuticals’ (ASX:CU6) news on Wednesday morning could offer crucial moral support.For those patients (who have also already received first-stage less ...

Clarity jumps as FDA awards fast track status for PET scan imaging agent

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the first hour of trade to $4.23 in what is likely a welcome move for shareholders who have already seen ...

Clarity progresses SECuRE trial with positive safety results

Clarity Pharmaceuticals Ltd has reported strong results from Cohort 4 of the SECuRE trial examining a treatment for prostate cancer

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News